Philips, the last of the global top-three imaging companies to report 2024 financial results, said the soft China market put the brakes on its growth. The regional outlook for early 2025 is no different, and US-China tariffs will present another challenge.

Improving reimbursement and integrating digital process across health care should be two priorities for the incoming German coalition, says Martin Walger, chief executive of the IVD industry association, the VDGH, in part two of his interview with In Vivo.

Medtechs watch with interest as NICE, a long-standing component of market access for innovative technologies in the National Health Service, vows to get to grips with technology programs that often miss the target for developers of groundbreaking solutions.

The US market’s largest imaging manufacturer marked two years as an independent company with plans to invest in more M&A and PDx production capacity, but reported a modest 2025 revenues outlook.

Lawmaking in Germany came to a halt after the federal election was called, meaning cardiovascular detection and pharmacy legislation were put on hold. In part one of a two-part interview on key themes for industry, Martin Walger, chief executive of the IVDs industry association, the VDGH, lays out the hopes and fears of IVD companies in the run up to the late February vote.

The MHRA’s post-market surveillance regulations for Great Britain will be followed in 2026 by a pre-market regulation, but its progress will not be steered by the agency’s erstwhile leader of device system transformation. The ABHI’s Steve Lee and Phil Brown ponder where national device system regulation – and the MHRA – go next.